Pizuglanstat is a potent, selective prostaglandin D synthase inhibitor..

Pirfenidone(AMR69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.

Piperaquine Phosphate

Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12.

Pilaralisib (SAR245408; XL147) is selective oral pan-PI3K inhibitor.

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.

Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM.

PH-797804 is a potent and selective p38 inhibitor with IC50 of 26 nM.

PH-002 is a small-molecule structure corrector,inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction,a potent candidate drug for the treament of AD(Alzheimer disease)

PGN-9856 (PGN9856) is a novel potent, selective prostaglandin EP2 receptor agonist with pKi of > 8.3, shows higi selectivity over EP1 , EP3 , EP4 , DP, FP, IP and TP receptors; displays a potency (pEC50 >8.5) and a maximal response (increase in cAMP) comp

PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies.

PFK-015 is an effective inhibitor of PFKFB3 with IC50 of 110 nM (recombinant PFKFB3) and inhibits PFKFB3 activity in cancer cells with IC50 of 20 nM.

PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC50 of 420 nM and a Kd of 170 nM.

PF-4708671 is a novel cell-permeable inhibitor of S6K1 (p70 ribosomal S6 kinase 1), with a Ki of 20 nM and IC50 of 160 nM.

PF-429242 is a potent inhibitor of S1P(cellular proprotein convertase sterol regulatory element-binding protein (SREBP) site 1 protease)

PF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.

PF06650833 is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. PF06650833 is used to treat diseases such as rheumatoid arthritis, l

PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.

PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, is a FGF21-receptor agonist, suitable for development as a potential treatment for T2DM.

PF-04457845 is a potent and exquisitely selective inhibitor of FAAH, with an IC50 of 7.2 nM, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen.

PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

PF 670462 is a selective casein kinase, CK1ε and CK1δ inhibitor which also shows potency against 42 other kinases.

Pemigatinib is a selective FGFR inhibitor in development for the treatment of patients with cholangiocarcinoma.

PBIT is a potent, cell-permeable inhibitor of Jumonji histone demethylase (JHDM). Innhibits JARID1B (also known as KDM5B or PLU1) with an IC₅₀ of about 3 μm in vitro.

Parthenolide is a sesquiterpene lactone from the plant feverfew (T. parthenium).

Palovarotene (R-667, RO-3300074) is a selective retinoic acid receptor gamma(RAR-γ) agonist for the treatment of emphysema.

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.

p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay.

PF-1355 is a potent, selective, orally active Myeloperoxidase (MPO) inhibitor with EC50 of 1.47 uM.